MOBILion Systems Showcases Innovative PAMAF Mode for Proteomics
Exploring Advanced Proteomics with MOBILion Systems
In the realm of proteomics, measurement accuracy and sensitivity are paramount. MOBILion Systems, Inc., is at the forefront of this revolution, showcasing their innovative technology at the prestigious US HUPO Conference. Their latest operating mode, Parallel Accumulation with Mobility Aligned Fragmentation (PAMAF), is transforming how researchers tackle complex biological analyses.
What is PAMAF?
PAMAF represents a significant advancement in the way mass spectrometry analyses are conducted. By employing high-resolution ion mobility separation instead of traditional quadrupole isolation methods, PAMAF dramatically improves fragmentation data quality. With tenfold enhancements in signal-to-noise ratios and five times the speed of standard systems, researchers can achieve deeper insights into protein structures and functions.
A New Era for Proteomics Research
Melissa Sherman, Ph.D., the CEO of MOBILion Systems, emphasizes the importance of PAMAF in cellular research. "Our PAMAF operating mode enables researchers to make more accurate analytical measurements and achieve deeper proteome characterization," she explained. The significance of this innovation cannot be understated, especially in sample-limited workflows such as single-cell proteomics.
Scientific Contributions at US HUPO 2025
At US HUPO 2025, researchers will present findings that highlight the capabilities of PAMAF beyond what traditional LC-MS methods can offer. One notable presentation includes an educational seminar led by Prof. Birgit Schilling from The Buck Institute for Research on Aging. Her team's research focuses on succinylation levels in models relevant to chronic kidney disease (CKD).
Impact of PAMAF on Research Outcomes
By employing PAMAF mode, Prof. Schilling's research team has identified numerous succinylation sites that could be pivotal in understanding kidney disease pathology. The ability to characterize modifications on a granular level is a breakthrough that affects not just CKD studies but a wide array of health research domains.
Key Presentations and Sessions
The scientific program at the conference will feature a diverse range of presentations that underline the application of PAMAF:
- Oral Presentation: "Abandoning the Quadrupole for MS Fragmentation Analysis" by Daniel DeBord, Ph.D., showcasing advancements in ion mobility technology.
Poster sessions will also be an essential part of the agenda, with topics covering performance metrics and highlights of PAMAF implementations in various proteomics applications.
Join the Educational Breakfast Seminar
On February 26, an educational breakfast seminar will delve into next-generation proteomics analysis using high-resolution ion mobility techniques. Experts, including Dr. Danel DeBord and Dr. Birgit Schilling, will share their latest findings and the future implications of this technology.
MOBILion Systems’ Commitment to Innovation
The commitment of MOBILion Systems to propel advances in proteomics is clear. By exhibiting at the US HUPO Conference and engaging the scientific community, they are not only showcasing their technology but also fostering collaboration and innovation across fields.
Exploring New Frontiers
MOBILion is located at booth number 18, where attendees can witness firsthand how PAMAF is setting new standards in proteomics research. This is an opportunity for professionals to engage with cutting-edge technologies that promise to reshape the understanding of complex biological systems.
About MOBILion Systems, Inc.
MOBILion Systems leads in next-generation separation science with their motto of revealing what others leave unseen. Their advanced tools are designed for deep, accurate, and efficient characterizations of complex samples. By integrating their technology with mass spectrometry, they are pushing the envelope in molecular characterization across multiple industries, including pharmaceuticals and food testing.
Frequently Asked Questions
What is the PAMAF mode developed by MOBILion Systems?
PAMAF stands for Parallel Accumulation with Mobility Aligned Fragmentation, a mode that significantly enhances speed and sensitivity in proteomics analysis.
What key presentations will occur at US HUPO 2025?
Key presentations include discussions on the benefits of PAMAF in complex protein analysis and educational seminars highlighting new research findings.
How does PAMAF improve proteomics research?
PAMAF improves research by providing higher signal-to-noise ratios and faster analysis speeds, enabling deeper characterizations of proteins.
Who can attend the MOBILion Systems booth at the conference?
The booth is open to all conference attendees interested in learning about new advancements in proteomics and mass spectrometry technologies.
What industries benefit from MOBILion's technologies?
MOBILion’s technologies benefit industries like pharmaceuticals, food safety, and environmental testing, making complex sample analysis more effective.
About The Author
Contact Lucas Young privately here. Or send an email with ATTN: Lucas Young as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
